The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae
暂无分享,去创建一个
[1] M. Herrmann,et al. Neutrophil Extracellular Traps Tied to Rheumatoid Arthritis: Points to Ponder , 2021, Frontiers in Immunology.
[2] M. Díaz-Ricart,et al. Response to Maccio et al, “Multifactorial pathogenesis of COVID‐19‐related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?” , 2020, Journal of Thrombosis and Haemostasis.
[3] C. Madeddu,et al. Multifactorial pathogenesis of COVID‐19‐related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders? , 2020, Journal of Thrombosis and Haemostasis.
[4] M. Díaz-Ricart,et al. Defibrotide inhibits donor leucocyte‐endothelial interactions and protects against acute graft‐versus‐host disease , 2020, Journal of cellular and molecular medicine.
[5] Kevin Grimes,et al. p38 MAPK inhibition: A promising therapeutic approach for COVID-19 , 2020, Journal of Molecular and Cellular Cardiology.
[6] V. Sheehan,et al. The Vaso-Occlusive Pain Crisis in Sickle Cell Disease: Definition, Pathophysiology, and Management. , 2020, European journal of haematology.
[7] Han-Hsuan Fu,et al. Defibrotide modulates pulmonary endothelial cell activation and protects against lung inflammation in pre-clinical models of LPS-induced lung injury and idiopathic pneumonia syndrome , 2020, Frontiers in Immunology.
[8] M. Díaz-Ricart,et al. Up‐regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide , 2019, Journal of cellular and molecular medicine.
[9] M. Díaz-Ricart,et al. Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide , 2019, Front. Immunol..
[10] G. Nishanth,et al. Blood-Brain Barrier in Cerebral Malaria: Pathogenesis and Therapeutic Intervention. , 2019, Trends in parasitology.
[11] A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity , 2019, Case Medical Research.
[12] J. Belsey,et al. Cost-Effectiveness of Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Multi-Organ Dysfunction (MOD) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Canada , 2018, Blood.
[13] H. Pass,et al. Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications , 2018, Journal of the National Cancer Institute.
[14] P. Richardson,et al. The use of defibrotide in blood and marrow transplantation. , 2018, Blood advances.
[15] P. Richardson,et al. Final results from a defibrotide treatment‐IND study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome , 2018, British journal of haematology.
[16] M. Wurfel,et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. , 2017, Cancer discovery.
[17] D. Markovitz,et al. DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis , 2017, Nature Communications.
[18] A. Gennery,et al. Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors Working Parties of the European Society of Blood and Marrow Transplantation , 2017, Bone Marrow Transplantation.
[19] K. Horibe,et al. Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects , 2016, Clinical pharmacology in drug development.
[20] M. Díaz-Ricart,et al. What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance. , 2016, Blood.
[21] R. D'Agostino,et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. , 2016, Blood.
[22] S. Giralt,et al. Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[23] H. Batgi,et al. Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation? , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[24] M. Abecassis,et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Bone Marrow Transplantation.
[25] J. Crawford,et al. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). , 2014, Journal of Clinical and Experimental Hepatology.
[26] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[27] S. Grupp,et al. Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.
[28] A. Fulgenzi,et al. Defibrotide: properties and clinical use of an old/new drug. , 2013, Vascular pharmacology.
[29] A. Schulz,et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial , 2012, The Lancet.
[30] R. Schwarz,et al. Defibrotide Interferes With Several Steps of the Coagulation-Inflammation Cycle and Exhibits Therapeutic Potential to Treat Severe Malaria , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[31] M. Díaz-Ricart,et al. Combining allografting with mTOR inhibitors for metastatic renal cell cancer , 2011, Bone Marrow Transplantation.
[32] M. Sweet,et al. Histone deacetylases as regulators of inflammation and immunity. , 2011, Trends in immunology.
[33] M. Díaz-Ricart,et al. Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[34] Allen R. Chen,et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[35] A. Nagler,et al. Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. , 2010, Blood.
[36] G. Wang,et al. Histone Deacetylase 3 Is Critical in Endothelial Survival and Atherosclerosis Development in Response to Disturbed Flow , 2010, Circulation.
[37] P. Richardson,et al. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[38] M. Iacobelli,et al. Prolonged Administration of Defibrotide Is Non-Immunogenic in Rats and Dogs. , 2009 .
[39] K. Anderson,et al. Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias , 2009, Clinical Cancer Research.
[40] P. Richardson,et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. , 2008, Blood.
[41] W. Aird. Endothelium in health and disease. , 2008, Pharmacological reports : PR.
[42] G. Koehl,et al. Defibrotide: An endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo , 2007, Cancer biology & therapy.
[43] O. Wendler,et al. Expression and function of laminins in the embryonic and mature vasculature. , 2005, Physiological reviews.
[44] K. Schrör,et al. Selective stimulation of coronary vascular PGI2 but not of platelet thromboxane formation by defibrotide in the platelet perfused heart , 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.
[45] C. Legnani,et al. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man , 2004, European Journal of Clinical Pharmacology.
[46] T. Barbui,et al. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells , 2003, Leukemia.
[47] D. Perry,et al. Veno-occlusive disease: cytokines, genetics, and haemostasis. , 2003, Blood reviews.
[48] J. Chang,et al. Role of Plasminogen Activator Inhibitor-1 (PAI-1) Levels in the Diagnosis of BMT-associated Hepatic Veno-occlusive Disease and Monitoring of Subsequent Therapy with Defibrotide (DF) , 2003, Hematology.
[49] Allen R. Chen,et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. , 2002, Blood.
[50] S. Kirchner,et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. , 2002, Blood.
[51] D. Hoppensteadt,et al. Tissue Factor Pathway Inhibitor Release Induced by Defibrotide and Heparins , 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[52] S. Friedman. Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury* , 2000, The Journal of Biological Chemistry.
[53] D. Neuberg,et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. , 1998, Blood.
[54] B. Hunt,et al. Endothelial cell activation , 1998, BMJ.
[55] W. Wilmanns,et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. , 1997, Blood.
[56] B. Campbell,et al. Effects of defibrotide on leukocyte-endothelial cell interaction in the rat mesenteric vascular bed: role of P-selectin. , 1996, Methods and findings in experimental and clinical pharmacology.
[57] S. Chierchia,et al. Drug‐induced in vitro inhibition of neutrophil‐endothelial cell adhesion , 1996, British journal of pharmacology.
[58] G. Maurer,et al. Thrombolytic Therapy in Acute Myocardial Infarction , 1996, Seminars in thrombosis and hemostasis.
[59] F. Pasini,et al. Modulation of venous endothelial activity and transcellular calcium transport by defibrotide: the adenosine hypothesis. , 1996, Seminars in thrombosis and hemostasis.
[60] S. Bearman,et al. The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.
[61] K. Schrör,et al. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. , 1994, Biochemical and biophysical research communications.
[62] Quansheng Zhou,et al. Defibrotide Stimulates Expression of Thrombomodulin in Human Endothelial Cells , 1994, Thrombosis and Haemostasis.
[63] K. Goa,et al. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. , 1993, Drugs.